Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Veracyte Inc VCYT

Healthcare Diagnostics & Research
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab... see more

Current News (NDAQ:VCYT)

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Business Wire 13 days ago

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Business Wire December 29, 2025

Veracyte to Participate in Upcoming Investor Conferences

Business Wire November 6, 2025

Veracyte Announces Third Quarter 2025 Financial Results

Business Wire November 4, 2025

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Business Wire November 3, 2025

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Business Wire October 15, 2025

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Business Wire September 28, 2025

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Business Wire September 24, 2025

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Business Wire September 9, 2025
View More News ››

Opinion & Analysis (NDAQ:VCYT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VCYT)

Veracyte (NASDAQ:VCYT) – A Genomic Diagnostics Leader

http://beyondspx.com/2024/08/01/veracyte-nasdaqvcyt-a-genomic-diagnostics-leader-poised-for-continued-growth/
MikeTester - August 2, 2024
View more Bullboard ››

Kobrea Exploration Corp.

Kobrea Exploration Corp.

Kobrea Exploration Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. It holds a ...
View More »

Podcasts